

George J Bosl

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6148524/george-j-bosl-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

9,354
citations

57
h-index

92
g-index

175
ext. papers

10,537
ext. citations

5
avg, IF

5.46
L-index

#	Paper	IF	Citations
169	Testicular germ-cell cancer. <i>New England Journal of Medicine</i> , 1997 , 337, 242-53	59.2	720
168	Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. <i>Journal of Urology</i> , 1998 , 159, 133-8	2.5	310
167	Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6549-55	2.2	283
166	Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 247-56	2.2	256
165	Medical treatment of advanced testicular cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 672-84	27.4	253
164	Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. <i>Cancer Research</i> , 2006 , 66, 820-7 ^{10.1}		243
163	Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2413-8	2.2	195
162	Teratoma with malignant transformation in germ cell tumors in men. <i>Cancer</i> , 1985 , 56, 860-3	6.4	193
161	Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3752-63	2.2	189
160	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. <i>Cancer</i> , 1985 , 55, 527-34	6.4	188
159	Chemotherapy for teratoma with malignant transformation. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4285-91		172
158	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. <i>Journal of Urology</i> , 1988 , 139, 470-4	2.5	171
157	Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1173-80	2.2	157
156	Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2781-8	2.2	153
155	TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1706-13	2.2	150
154	CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. <i>Radiology</i> , 2011 , 258, 41-56	20.5	143
153	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. <i>Oncogene</i> , 1998 , 16, 2345-9	9.2	133

152	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997 , 157, 860-862	2.5	128
151	Clinical stage I testis cancer: long-term outcome of patients on surveillance. <i>Journal of Urology</i> , 1998 , 159, 855-8	2.5	118
150	Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 1993 , 8, 230-6	5	116
149	Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4365-9 ^{2.2}	2.2	111
148	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4000-4007	2.2	110
147	Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. <i>Molecular Cancer</i> , 2004 , 3, 16	42.1	107
146	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990 , 66, 2476-81	6.4	103
145	Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). <i>Cancer</i> , 1991 , 67, 1305-10	6.4	102
144	Leukemic differentiation of a mediastinal germ cell tumor. <i>Genes Chromosomes and Cancer</i> , 1989 , 1, 83-75		98
143	Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 85-90	2.2	91
142	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992 , 69, 550-6	6.4	91
141	Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5597-602	2.2	90
140	Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 60-2	9.7	89
139	Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. <i>Cancer</i> , 1994 , 74, 1329-34	6.4	89
138	Extragenital and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. <i>Cancer</i> , 1991 , 67, 2049-57	6.4	87
137	Clinical outcome and predictors of survival in late relapse of germ cell tumor. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5524-9	2.2	84
136	Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. <i>Journal of Clinical Oncology</i> , 2001 , 19, 682-8	2.2	84
135	Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. <i>Journal of Urology</i> , 2005 , 174, 557-60; discussion 560	2.5	80

134	Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. <i>American Journal of Pathology</i> , 2002 , 161, 365-71	5.8	80
133	Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. <i>Journal of Urology</i> , 2007 , 177, 937-42; discussion 942-3	2.5	77
132	Characteristic promoter hypermethylation signatures in male germ cell tumors. <i>Molecular Cancer</i> , 2002 , 1, 8	42.1	77
131	Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2020-5	2.2	77
130	Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 3712-20	12.9	75
129	Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9290-4	2.2	74
128	Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. <i>Head and Neck</i> , 1996 , 18, 405-11	4.2	74
127	Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5603-8	2.2	73
126	Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992 , 70, 2354-7	6.4	73
125	Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003 , 62, 732-6	1.6	72
124	Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. <i>International Journal of Surgical Pathology</i> , 2002 , 10, 23-32	1.2	72
123	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , 2009 , 22, 1066-74	9.8	71
122	Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 464-7	2.2	70
121	Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. <i>Cancer</i> , 1986 , 57, 978-83	6.4	70
120	Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1033-7	2.2	69
119	Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. <i>PLoS ONE</i> , 2012 , 7, e51563	3.7	67
118	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , 1994 , 73, 2520-6	6.4	63
117	Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5240-7	2.2	62

116	Biology and genetics of adult male germ cell tumors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5512-8	2.2	61
115	Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6999-7004	2.2	61
114	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , 2007 , 109, 528-35	6.4	60
113	Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma?. <i>Genes Chromosomes and Cancer</i> , 1991 , 3, 122-7	5	59
112	Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2980-7 ²		56
111	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010 , 28, 523-8	4.3	55
110	The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. <i>Journal of Urology</i> , 1994 , 152, 111-3; discussion 114	2.5	55
109	Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. <i>Journal of Urology</i> , 2006 , 176, 100-3; discussion 103-4	2.5	52
108	Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. <i>Journal of Urology</i> , 2003 , 170, 1159-62	2.5	50
107	Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991 , 21, 703-8	4	50
106	Tumor markers in advanced nonseminomatous testicular cancer. <i>Cancer</i> , 1981 , 47, 572-6	6.4	49
105	Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , 2005 , 24, 5101-7	9.2	48
104	Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 1994 , 111, 31-7	5.5	48
103	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , 1981 , 47, 328-32	6.4	48
102	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3525-3528	2.2	45
101	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. <i>Cancer</i> , 2012 , 118, 981-6	6.4	44
100	Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1992 , 5, 21-9	5	42
99	Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 7405-11	12.9	40

98	Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1236-41	8.9	39
97	A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. <i>Head and Neck</i> , 1998 , 20, 497-503 ⁴⁻²		39
96	The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. <i>Urology</i> , 2010 , 75, 1431-5	1.6	36
95	Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. <i>Journal of Urology</i> , 2014 , 192, 415-9	2.5	34
94	Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors. <i>Genomics</i> , 1996 , 35, 562-70	4.3	34
93	Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases. <i>Cancer</i> , 1982 , 50, 1591-5	6.4	32
92	Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994 , 73, 2843-52	6.4	31
91	Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2006 , 12, 182-8	2.2	30
90	Decompression of epidural metastases from germ cell tumors with chemotherapy. <i>Journal of Neuro-Oncology</i> , 1990 , 8, 275-80	4.8	30
89	RECOGNIZING ABNORMAL MARKER RESULTS THAT DO NOT REFLECT DISEASE IN PATIENTS WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 2000 , 163, 796-801	2.5	29
88	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995 , 76, 680-6	6.4	29
87	VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984 , 7, 327-30	2.7	29
86	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998 , 17, 761-7	9.2	28
85	Two-drug therapy in patients with metastatic germ cell tumors. <i>Cancer</i> , 1991 , 67, 28-32	6.4	28
84	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990 , 65, 2465-70	6.4	28
83	Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2221-5	2.2	27
82	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015 , 138, 566-72	4.9	27
81	Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007 , 99, 993-7	5.6	25

80	Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995 , 13, 163-5	4.3	25
79	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2478-83	2.2	25
78	Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. <i>Stem Cells</i> , 2015 , 33, 367-77	5.8	24
77	Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. <i>BJU International</i> , 2009 , 104, 1334-8	5.6	24
76	Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. <i>Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , 2002 , 13, 257-64		24
75	Sarcoidosis, "Sarcoid-like lymphadenopathy," and testicular germ cell tumors. <i>American Journal of Medicine</i> , 1990 , 89, 651-6	2.4	22
74	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013 , 119, 2574-81	6.4	21
73	Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2679-88	2.2	21
72	Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. <i>Urology</i> , 2012 , 79, 156-9	1.6	20
71	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , 2012 , 91, 379-83	11	20
70	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010 , 116, 5243-50	6.4	20
69	Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007 , 25, 487-90	4.3	20
68	Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. <i>Journal of Urology</i> , 2003 , 170, 1155-8	2.5	20
67	Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. <i>Functional and Integrative Genomics</i> , 2005 , 5, 59-69	3.8	20
66	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993 , 72, 3313-7	6.4	20
65	Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. <i>Urology</i> , 1983 , 21, 559-61	1.6	20
64	Carboplatin in clinical stage I seminoma: too much and too little at the same time. <i>Journal of Clinical Oncology</i> , 2011 , 29, 949-52	2.2	19
63	Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003 , 62, 1092-6	1.6	19

62	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008 , 112, 800-5	6.4	18
61	Carboplatin for stage I seminoma and the sword of Damocles. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8566-9	3.3	17
60	Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. <i>Urology</i> , 2013 , 82, 1341-6	1.6	16
59	Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. <i>Urology</i> , 2012 , 79, 361-4	1.6	16
58	Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. <i>Cancer</i> , 1983 , 51, 2121-5	6.4	16
57	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015 , 10, e0142846	3.7	16
56	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e761-e769	3.3	15
55	Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. <i>Cancer</i> , 1991 , 67, 1299-304	6.4	15
54	Malignant carcinoid of the gallbladder: third reported case and review of the literature. <i>Journal of Surgical Oncology</i> , 1980 , 13, 215-22	2.8	15
53	A 3-Mb High-Resolution BAC/PAC Contig of 12q22 Encompassing the 830-kb Consensus Minimal Deletion in Male Germ Cell Tumors. <i>Genome Research</i> , 1999 , 9, 662-671	9.7	14
52	miR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cells. <i>Stem Cells and Development</i> , 2014 , 23, 1149-56	4.4	13
51	Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 519-21	2.2	13
50	ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993 , 20, 111-116	2.9	13
49	Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. <i>Journal of Urology</i> , 2015 , 193, 513-8	2.5	12
48	Contemporary lymph node counts during primary retroperitoneal lymph node dissection. <i>Urology</i> , 2011 , 77, 368-72	1.6	12
47	Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2004 , 22, 177-9	4.3	12
46	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2329-2337	2.2	11
45	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992 , 10, 327-30	4.3	11

44	A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 557-76, viii -ix	3.1	10
43	Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. <i>Stem Cells</i> , 2007 , 25, 771-8	5.8	10
42	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , 2018 , 36, 837-840	2.2	10
41	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017 , 103, 154-160	1.6	9
40	Time to publication of oncology trials and why some trials are never published. <i>PLoS ONE</i> , 2017 , 12, e0184025	9.7	9
39	Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. <i>BJU International</i> , 2012 , 110, 950-5	5.6	8
38	Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. <i>Urology</i> , 2011 , 77, 655-9	1.6	8
37	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000 , 18, 265-7	4.3	8
36	Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. <i>Cancer</i> , 2011 , 117, 1911-6	6.4	7
35	Germ cell tumor clinical trials in North America. <i>Journal of Surgical Oncology</i> , 1999 , 17, 257-62		7
34	High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999). <i>International Journal of Cancer</i> , 1999 , 83, 834-8	7.5	7
33	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018 , 114, 133-138	1.6	6
32	Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification. <i>Stem Cell Reports</i> , 2016 , 6, 772-783	8	6
31	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017 , 197, 391-397	2.5	6
30	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , 2008 , 1, 22	22.4	6
29	830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007 , 177, 277-277	2.5	6
28	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016 , 95, 128-31	1.6	6
27	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018 , 118, 114-118	1.6	5

26	Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. <i>Urology</i> , 2012 , 79, 1079-84	1.6	5
25	Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 595-600	4.7	5
24	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021 , 274, e1099-e1107	7.8	5
23	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
22	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1332-1337	2.2	4
21	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. <i>Urology</i> , 2019 , 124, 174-178	1.6	4
20	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 453-60	3.3	3
19	The future of therapy for nonseminomatous germ cell tumors. <i>Chest Surgery Clinics of North America</i> , 2002 , 12, 769-89		3
18	Expression of ID genes in differentiated elements of human male germ cell tumors. <i>Diagnostic Molecular Pathology</i> , 2001 , 10, 248-54		3
17	Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy. <i>Cancer</i> , 1987 , 60, 312-7	6.4	3
16	Status and prospects of the treatment of disseminated germ-cell tumors. <i>World Journal of Urology</i> , 1984 , 2, 38-42	4	3
15	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021 , 26, 483-491	5.7	2
14	Surgery of Testicular Tumors 2012 , 871-892.e6		1
13	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1141-1149	2.7	1
12	Recurrent Germ Cell Tumors: Let's Try to Cure Them All. <i>Journal of Oncology Practice</i> , 2016 , 12, 445-7	3.1	1
11	Testicular granulosa cell tumors: rare tumors need to be studied too. <i>Oncology</i> , 2009 , 23, 796	1.8	1
10	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e740-e740	2.2	0
9	Advances in urologic oncology: results progress from successful interdisciplinary research. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5479-81	2.2	0

- 8 Reply to L.H. Einhorn et al. *Journal of Clinical Oncology*, **2020**, 38, 3074-3075 2.2
- 7 Reply: To PMID 24094653. *Urology*, **2013**, 82, 1346-7 1.6
- 6 Germ cell tumors: looking to the future. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e253-8 7.1
- 5 Reply to S. Stenning et al and J. Lipshitz. *Journal of Clinical Oncology*, **2011**, 29, 4211-4212 2.2
- 4 Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. *Nature Clinical Practice Oncology*, **2007**, 4, 508-9
- 3 Genetics and Biology of Adult Male Germ Cell Tumors **2005**, 221-229
- 2 Germ Cell Tumors **2002**, 287-296
- 1 Advances in the Understanding of Germ Cell Tumour Biology **2002**, 23-29